글로벌 백신 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

백신 시장 분석  

글로벌 백신 시장은 예방 의료에 대한 인식 증가와 백신 기술의 발전에 힘입어 강력한 성장을 보이고 있습니다. 최근 개발에는 특히 COVID-19 팬데믹 동안 강조된 mRNA 백신 의 빠른 배포가 포함되며 , 이는 다양한 감염성 질환에 대한 미래 백신 개발의 선례를 만들었습니다. 이 혁신적인 기술은 백신 개발 일정을 가속화하고 효능과 안전성을 향상시킬 수 있는 잠재력을 보여주었습니다. 또한 복합 백신에 대한 지속적인 연구는 단일 샷으로 여러 질병에 대한 면역을 가능하게 하여 시장을 확대하고 있으며, 이를 통해 환자 준수와 적용률을 개선하고 있습니다. 규제 기관은 또한 새로운 백신에 대한 빠른 승인을 촉진하는 데 핵심적인 역할을 하여 새로운 건강 위협에 대한 적시 대응을 가능하게 했습니다. 게다가 백신으로 예방할 수 있는 질병의 유병률이 증가하고 환자 인구가 증가함에 따라 시장 수요가 촉진되고 있습니다. 특히 저소득 및 중소득 국가에서 백신 접종 프로그램을 확대하기 위한 정부 이니셔티브도 시장 성장에 기여하고 있습니다. 이러한 발전으로 백신 시장은 지속적인 확장을 준비하고 있으며, 글로벌 건강 결과를 개선하고 감염성 질환으로 인한 과제를 해결할 수 있습니다.

백신 시장 규모

글로벌 백신 시장 규모는 2023년에 748억 달러로 평가되었으며, 2031년까지 1,686억 9,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.70%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

백신 시장 동향

“ 혁신적인 백신 솔루션에 대한 수요 증가”

The global vaccine market is experiencing significant growth, fueled by the increasing demand for innovative vaccination solutions and a heightened focus on public health. One notable trend is the shift towards mRNA vaccine technology, which gained prominence during the COVID-19 pandemic with the successful deployment of vaccines like Pfizer-BioNTech and Moderna. Such technology allowed for rapid development and high efficacy rates and opened new avenues for addressing other infectious diseases, such as influenza and Zika virus, through similar platforms. Furthermore, the rise of combination vaccines is enhancing market dynamics, enabling healthcare providers to deliver immunizations for multiple diseases in a single dose, thereby improving patient adherence. The pentavalent vaccine, offering protection against five diseases, exemplifies this trend by fulfilling the need for broader immunization strategies. As public awareness and government support for vaccination initiatives continue to grow, the vaccine market is well-positioned to expand, contributing to improved health outcomes globally.

Report Scope and Vaccine Market Segmentation      

Vaccine Market Definition

Vaccines are biological preparations designed to provide immunity against specific infectious diseases. They typically contain weakened or inactivated forms of pathogens (such as viruses or bacteria), or components of these pathogens, such as proteins or sugars. When administered, vaccines stimulate the immune system to recognize and remember the pathogen, allowing the body to mount a faster and more effective response if exposed to the actual disease in the future. This process helps to prevent illness and reduce the spread of infectious diseases within communities. Vaccines can be delivered through various routes, including injections, oral formulations, and nasal sprays, and are a crucial component of public health strategies worldwide.

Vaccine Market Dynamics

Drivers

• Rising Incidence of Infectious Diseases

The rising global incidence of infectious diseases is a significant driver of vaccine demand. Recent outbreaks of illnesses such as measles, influenza, and COVID-19 have highlighted the essential role of vaccination in controlling the spread of infectious diseases and lessening their impact on public health. According to data from the World Health Organization (WHO) released in July 2023, coverage of the third dose of the diphtheria, tetanus, and pertussis (DTP3) vaccine increased from 81% in 2021 to 84% in 2022. In addition, the percentage of children receiving the first dose of the measles vaccine rose slightly from 81% in 2021 to 83% in 2022. These results reflect advancements in global vaccination efforts and a growing emphasis on immunization programs worldwide, further enhancing the vaccine market.

• Increased Funding for Vaccine Research

The increase in funding for vaccine research from government bodies and private organizations is driving the development of new vaccines and expanding the market. Project NextGen, initiated by the U.S. Department of Health and Human Services (HHS), aims to expedite and enhance the rapid development of next-generation vaccines and treatments through public-private partnerships, backed by an initial investment of USD 5 billion. This surge in funding is facilitating research efforts focused on a diverse range of diseases, including emerging infectious diseases and cancer. As a result, there is a strong pipeline of new vaccines that address unmet medical needs and stimulate market growth.

Opportunities

• Expansion of Vaccination Programs

Expansion of Vaccination Programs is significantly transforming the market, especially in developing countries where access to vaccines remains limited. According to the World Health Organization (WHO), data from various nations reveal that barriers and inequities in access to pediatric vaccines continue to exist, with the rotavirus vaccine being utilized in only 58% of self-procuring middle-income countries. Likewise, the human papillomavirus vaccine is administered in only 41% of lower-income countries, despite these nations facing a considerable burden from cervical cancer and having limited access to other preventive and curative healthcare services. Increasing investments in healthcare infrastructure and vaccination initiatives can enhance vaccine coverage and mitigate the impact of vaccine-preventable diseases in these regions, presenting a substantial market opportunity for vaccine manufacturers.

• Development of Next-Generation Vaccines

The emergence of next-generation vaccines, including mRNA and recombinant vaccines, offers significant opportunities for innovation and growth in the market. These vaccines provide benefits such as faster development timelines, enhanced efficacy, and improved safety profiles. The acquisition of Affinivax, Inc. by GSK plc illustrates the potential associated with next-generation vaccines in the market. Affinivax’s groundbreaking efforts in creating next-generation pneumococcal vaccines, such as AFX3772, highlight the capacity of these vaccines to deliver substantial improvements over traditional vaccine technologies. Companies like GSK are investing in the development of next-generation vaccines to address the evolving needs of healthcare systems worldwide, thereby creating new opportunities for growth and innovation in the vaccine sector.

Restraints/Challenges

• Involved Adverse Reactions and Side Effects

High development costs represent a significant challenge in the vaccines market, as the research and development (R&D) phase is often both expensive and time-consuming. For instance, developing a new vaccine can require billions of dollars and several years of research, which includes preclinical studies, clinical trials, and regulatory approvals. The development of the COVID-19 vaccines, where companies like Moderna and Pfizer invested heavily in R&D, often supported by government funding and partnerships. However, pharmaceutical companies targeting less profitable markets, such as vaccines for neglected tropical diseases, face additional financial risks. These markets often lack sufficient return on investment, leading to fewer companies willing to invest in the necessary research. Consequently, this financial burden can deter innovation and limit the availability of vaccines for diseases that predominantly affect low-income populations, thereby impacting global vaccines market.

• Cold Chain Requirements

Cold chain requirements present a significant market challenge in the vaccine distribution process, as many vaccines need to be stored and transported at specific temperature ranges to maintain their efficacy and safety, directly impacting market accessibility and effectiveness. For instance, vaccines like the Pfizer-BioNTech COVID-19 vaccine initially required ultra-low temperature storage at around -70 degrees Celsius (-94 degrees Fahrenheit), complicating logistics and limiting accessibility, particularly in low-resource settings where such infrastructure is often lacking. Such challenge is further exacerbated by the fact that even with more stable vaccines, maintaining the cold chain can be difficult due to power outages, inadequate refrigeration facilities, and transportation issues in remote areas. Consequently, these logistical hurdles can lead to vaccine spoilage, reduced supply, and increased costs, ultimately hampering vaccination efforts and limiting market growth potential.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Vaccine Market Scope

The market is segmented on the composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Composition

• Combination Vaccines
• Monovaccines

Type

• Subunit Vaccines
• Recombinant Vaccines
• Polysaccharide Vaccines
• Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• DNA Vaccines

Kind

• Routine Vaccine
• Recommended Vaccine
• Required Vaccine

Age of Administration

• Pediatric Vaccine
• Adult Vaccine

Diseases

• Pneumococcal Disease
• Measles
• Mumps and Varicella
• DPT (Diphtheria, Pertussis, and Tetanus)
• Hepatitis
• Influenza
• Typhoid
• Meningococcal
• Rabies
• Japanese Encephalitis
• Yellow Fever
• Others

Route of Administration

• Injectable
• Oral
• Nasal

End User

• Community Hospitals
• Hospitals
• Specialty Centres
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Vaccine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the market, driven by its strong healthcare infrastructure and the presence of prominent industry players. The introduction of innovative vaccines, including those for rotavirus, pneumococcal conjugate, and human papillomavirus, presents significant opportunities for cost reduction and the establishment of new supply chains and distribution networks. Moreover, the region's investment in research and development, coupled with favorable government policies, further enhances the potential for growth in vaccine production and accessibility, ultimately benefiting public health initiatives across the continent.

아시아 태평양 지역은 향후 몇 년 동안 환자 인구가 확대되어 향상된 의료 서비스가 필요함에 따라 상당한 성장을 경험할 것으로 예상됩니다. 또한 의료 인프라와 기술에 대한 투자가 증가하여 서비스 제공과 의료 치료 접근성이 강화될 것입니다. 더욱이 강력한 정부 지원과 공공 보건 시스템 개선을 목표로 하는 이니셔티브는 이 역동적인 지역에서 의료 시장의 전반적인 개발과 확장에 기여할 가능성이 높습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.  

백신 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 백신 시장 리더는 다음과 같습니다.

• 머크앤코(미국)
• 파이저 주식회사(미국)
• GSK plc (영국)
• 사노피(프랑스)
• Serum Institute of India Pvt. Ltd. (인도)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Indian Immunologicals Ltd. (인도)
• 악스플로라(프랑스)
• 머크 KGaA(독일)
• 찰스 리버 연구소(영국)
• uniQure NV(네덜란드)
• 와이스먼 바이오매뉴팩처링(미국)
• 크리에이티브 바이오진(미국)
• 알데브론 LLC(미국)
• 애드진(미국)
• 옥스포드 바이오메디카 PLC(영국)
• Thermo Fisher Scientific Inc. (미국)
• 후지필름 주식회사(일본)
• Spark Therapeutics, Inc. (미국)

백신 시장의 최신 동향

• 2024년 5월, Novavax와 Sanofi는 COVID-19 백신을 공동 상용화하고 COVID-19와 독감을 모두 타겟으로 하는 혁신적인 복합 백신 개발에 협력하기 위한 공동 독점 라이선스 계약을 발표했습니다. 이 전략적 제휴를 통해 두 회사는 각자의 전문성과 리소스를 활용하여 시장에 고급 백신 솔루션을 제공할 수 있습니다.
• 2023년 3월, CSL Limited는 차세대 mRN을 포함한 파괴적 기술을 활용한 첨단 백신 개발을 목표로 매사추세츠주 월섬에 새로운 백신 연구 개발 시설을 열었습니다.

SKU-53099